Raymond James downgraded InVivo Therapeutics (NASDAQ: NVIV) from Strong Buy to Outperform with a price target of $6.00 (from $10.00).Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE